Cargando…
P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429291/ http://dx.doi.org/10.1097/01.HS9.0000846572.66058.38 |
| _version_ | 1784779394601975808 |
|---|---|
| author | Leypoldt, L. Gavriatopoulou, M. Besemer, B. Salwender, H. Raab, M.-S. Nogai, A. Khandanpour, C. Runde, V. Zago, M. Martus, P. Goldschmidt, H. Bokemeyer, C. Dimopoulos, M. Weisel, K. |
| author_facet | Leypoldt, L. Gavriatopoulou, M. Besemer, B. Salwender, H. Raab, M.-S. Nogai, A. Khandanpour, C. Runde, V. Zago, M. Martus, P. Goldschmidt, H. Bokemeyer, C. Dimopoulos, M. Weisel, K. |
| author_sort | Leypoldt, L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429291 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292912022-08-31 P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL Leypoldt, L. Gavriatopoulou, M. Besemer, B. Salwender, H. Raab, M.-S. Nogai, A. Khandanpour, C. Runde, V. Zago, M. Martus, P. Goldschmidt, H. Bokemeyer, C. Dimopoulos, M. Weisel, K. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429291/ http://dx.doi.org/10.1097/01.HS9.0000846572.66058.38 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Leypoldt, L. Gavriatopoulou, M. Besemer, B. Salwender, H. Raab, M.-S. Nogai, A. Khandanpour, C. Runde, V. Zago, M. Martus, P. Goldschmidt, H. Bokemeyer, C. Dimopoulos, M. Weisel, K. P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL |
| title | P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL |
| title_full | P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL |
| title_fullStr | P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL |
| title_full_unstemmed | P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL |
| title_short | P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL |
| title_sort | p926: daratumumab, bortezomib and dexamethasone for treatment of patients with relapsed or refractory multiple myeloma and severe renal impairment: results from the phase 2 gmmg-dante trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429291/ http://dx.doi.org/10.1097/01.HS9.0000846572.66058.38 |
| work_keys_str_mv | AT leypoldtl p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT gavriatopouloum p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT besemerb p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT salwenderh p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT raabms p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT nogaia p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT khandanpourc p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT rundev p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT zagom p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT martusp p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT goldschmidth p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT bokemeyerc p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT dimopoulosm p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial AT weiselk p926daratumumabbortezomibanddexamethasonefortreatmentofpatientswithrelapsedorrefractorymultiplemyelomaandsevererenalimpairmentresultsfromthephase2gmmgdantetrial |